Results 91 to 100 of about 19,765 (240)

Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects

Journal of Indian Society of Periodontology, 2010
Background and Objectives: Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis.
Veena H, Prasad Deepak
doaj  

Effect of early intra ⁃ articular injection of alendronate in reducing subchondral bone loss in rat mandibular condyle after ovariectomy

口腔疾病防治, 2017
Objective To investigate the effects of intra⁃articular injection of alendronate on the mandibular condyle in ovariectomized rats. Methods Sixty female rats were randomly divided into five groups: ovariectomy with vehicle treat⁃ ment alone, early ...
ZHU Song⁃ song
doaj   +1 more source

The acute effects of exercise intensity and inorganic nitrate supplementation on the Buckberg ratio in postmenopausal females

Experimental Physiology, EarlyView.
Abstract Menopause increases coronary heart disease risk, in part through reduced oestrogen‐mediated nitric oxide (NO) bioavailability. The Buckberg ratio, an index of myocardial oxygen supply–demand balance, in which higher values reflect more favourable myocardial perfusion, is lower in postmenopausal females (PMFs) than in age‐matched males.
Cassandra C. Derella, Austin C. Hogwood, Joaquin Ortiz de Zevallos, Nathan R. Weeldreyer, Kaitlin M. Love, Arthur Weltman, Jason D. Allen   +6 more
wiley   +1 more source

ALENDRONATE-INDUCED RESPIRATORY DISTRESS [PDF]

, 2020
Respiratory distress is a rare adverse effect of alendronate that is typically associated with severe dyspnoea and wheezing and typically requires hospitalization.
M, PRAVALIKA, V, SRIVANI, PAMU, SAGAR
core   +1 more source

Nitrogen‐Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study

International Journal of Cancer, Volume 159, Issue 7, Page 1669-1685, 1 October 2026.
Bisphosphonates are widely used to treat osteoporosis and to manage bone metastases in patients with breast cancer. Nitrogen‐based bisphosphonates may also broadly reduce cancer risk, but evidence remains inconsistent. This large population‐based data linkage study in women aged > 50 years found that, compared to no use of osteoporosis medicines ...
Karen M. Tuesley, Fiona Caristo, Katrina Spilsbury, Sallie‐Anne Pearson, Peter Donovan, Michael D. Coory, Christopher B. Steer, Susan J. Jordan   +7 more
wiley   +1 more source

Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis.

PLoS ONE, 2017
BackgroundOsteoporotic vertebral fractures adversely impact quality of life and also increase the risk of infection and mortality. Alendronate treatment increases bone mass and reduces the risk of fractures in patients with osteoporosis by suppressing ...
Ying-Chou Chen, Wei-Che Lin
doaj   +1 more source

Fracture Risk Associated With Long‐Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population‐Based Study Using National Claims Data (Système National des Données de Santé)

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective This retrospective cohort study evaluated the long‐term discontinuation (LTD) of osteoporosis treatments in postmenopausal women in France and associated fracture risk and economic burden. Methods From the national French health care database (Système National des Données de Santé), we included postmenopausal women aged ≥60 years initiating ...
Audrey Lajoinie, Meriem Benmerad, Magali Laborey, Pascale Samama, Gaëlle Désaméricq, Leila Chelbani, Karine Briot   +6 more
wiley   +1 more source

Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal

, 2000
We studied the effect on bone mass of alendronate treatment for 5 yr and its withdrawal. Four hundred and forty-seven postmenopausal women with normal bone mass entered a 3-yr randomized trial followed by a 2-yr open label extension.
Weiss, S R, Rodriguez-Portales, J A, Ravn, P, Weiss, SR, Yates, AJ, Fogelman, I, Krupa, D, Sambrook, P, McClung, MR, McClung, M R, Yates, A J, ?, ?, Rodriguez Portales, JA, Gilchrist, NL, Alendronate Osteoporosis Preventio, Fuleihan, G E, Gilchrist, N L, El Hajj Fuleihan, G, Wasnich, RD, Daifotis, A, Wasnich, R D   +20 more
core   +1 more source

The comparison of effects of alendronate and raloxifene treatment in postmenauposal women with osteoporosis - Original Investigation

, 2005
This study was performed to compare and to research the effects of raloxifene and alendronate for the treatment of postmenopausal osteoporosis women. Thirty two women with postmenopausal osteoporosis (raloxifene group:16 patients, alendronate group: 16 ...
Ayhan Erkek, Cavidan Ay, Ömer Faruk Şendur, Bengü Beydağ Odabaşı, Gülcan Gürer   +4 more
core  

Alendronate therapy in men with primary hyperparathyroidism.

, 2009
OBJECTIVE: To determine the skeletal effects of alendronate therapy in men with primary hyperparathyroidism (PHPT) in comparison with those in postmenopausal women. METHODS: There essentially are no published data on the effects of bisphosphonate therapy
Syed, ZA, Standish, TI, Khan, AA, Dubois, SJ, Bilezikian, JP, Kung, A   +5 more
core   +1 more source